Walvax BioTech - Asset Resilience Ratio

Latest as of June 2025: 2.20%

Walvax BioTech (300142) has an Asset Resilience Ratio of 2.20% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Walvax BioTech (300142) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥308.17 Million
≈ $45.09 Million USD Cash + Short-term Investments

Total Assets

CN¥14.00 Billion
≈ $2.05 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2022)

This chart shows how Walvax BioTech's Asset Resilience Ratio has changed over time. See Walvax BioTech net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Walvax BioTech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Walvax BioTech.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥308.17 Million 2.2%
Total Liquid Assets CN¥308.17 Million 2.20%

Asset Resilience Insights

  • Limited Liquidity: Walvax BioTech maintains only 2.20% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Walvax BioTech Industry Peers by Asset Resilience Ratio

Compare Walvax BioTech's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Aurobindo Pharma Limited
NSE:AUROPHARMA
Drug Manufacturers - Specialty & Generic 1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Xeris Pharmaceuticals Inc
NASDAQ:XERS
Drug Manufacturers - Specialty & Generic 0.00%
Procter & Gamble Health Limited
NSE:PGHL
Drug Manufacturers - Specialty & Generic 33.01%

Annual Asset Resilience Ratio for Walvax BioTech (2013–2022)

The table below shows the annual Asset Resilience Ratio data for Walvax BioTech.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 -0.25% CN¥-38.16 Million
≈ $-5.58 Million
CN¥15.34 Billion
≈ $2.24 Billion
+0.08pp
2021-12-31 -0.33% CN¥-45.05 Million
≈ $-6.59 Million
CN¥13.67 Billion
≈ $2.00 Billion
+0.17pp
2020-12-31 -0.50% CN¥-48.19 Million
≈ $-7.05 Million
CN¥9.65 Billion
≈ $1.41 Billion
+0.18pp
2019-12-31 -0.68% CN¥-47.52 Million
≈ $-6.95 Million
CN¥7.02 Billion
≈ $1.03 Billion
-0.12pp
2018-12-31 -0.56% CN¥-40.24 Million
≈ $-5.89 Million
CN¥7.24 Billion
≈ $1.06 Billion
+0.29pp
2017-12-31 -0.84% CN¥-49.59 Million
≈ $-7.26 Million
CN¥5.88 Billion
≈ $859.84 Million
+0.13pp
2016-12-31 -0.98% CN¥-61.90 Million
≈ $-9.06 Million
CN¥6.32 Billion
≈ $925.40 Million
-1.43pp
2015-12-31 0.45% CN¥28.10 Million
≈ $4.11 Million
CN¥6.26 Billion
≈ $915.72 Million
+0.54pp
2013-12-31 -0.09% CN¥-5.60 Million
≈ $-819.25K
CN¥6.14 Billion
≈ $897.87 Million
--
pp = percentage points

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.84 Billion
CN¥19.42 Billion CNY
Market Cap Rank
#5196 Global
#973 in China
Share Price
CN¥12.14
Change (1 day)
+4.21%
52-Week Range
CN¥10.44 - CN¥16.00
All Time High
CN¥93.63
About

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more